Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Inclusion Criteria: * Male severe hemophilic patients with undetectable FVIII activity \<1% or FIX activity \<2%, with or without inhibitors (any titer) are eligible. * Subjects with a past history of inhibitors (any inhibitor titer) are eligible. * Age ≥18 years. * Documentation of ≥4 bleeding episodes (any type or location of bleeds, treated or not) within the 6 months prior to screening. * For subjects on prophylaxis: Willingness to interrupt ongoing prophylaxis. * For subjects on immune tolerance induction (ITI): Willingness to interrupt ongoing ITI. Exclusion Criteria: * History of any other coagulation disorder (particularly disseminated intravascular coagulopathy or combined FVIII/FV deficiency) or platelet disorder. * History of diseases related to venous thromboembolic events (e.g., pulmonary embolism, deep vein thrombosis, thrombophlebitis) or thrombotic microangiopathy. * Risk factors for venous or arterial diseases (e.g., uncontrolled hypertension, uncontrolled diabetes). * History of cardiac, coronary and/or arterial peripheral atherosclerotic disease * Platelet count \<100,000/μL. * Human immunodeficiency virus (HIV) infection with a cluster of differentiation 4 (CD4+) lymphocyte count of \<200/mm\^3